- Home
- NXTC vs BLRX Comparison
NXTC vs BLRX Comparison
Compare NXTC & BLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NXTC
- BLRX
- Stock Information
- Founded
- NXTC 2015
- BLRX 2003
- Country
- NXTC United States
- BLRX Israel
- Employees
- NXTC N/A
- BLRX N/A
- Industry
- NXTC Biotechnology: Pharmaceutical Preparations
- BLRX Biotechnology: Pharmaceutical Preparations
- Sector
- NXTC Health Care
- BLRX Health Care
- Exchange
- NXTC Nasdaq
- BLRX Nasdaq
- Market Cap
- NXTC 9.3M
- BLRX 10.3M
- IPO Year
- NXTC 2019
- BLRX 2011
- Fundamental
- Price
- NXTC $0.43
- BLRX $2.95
- Analyst Decision
- NXTC Strong Buy
- BLRX Buy
- Analyst Count
- NXTC 2
- BLRX 2
- Target Price
- NXTC $3.50
- BLRX $26.00
- AVG Volume (30 Days)
- NXTC 259.7K
- BLRX 30.2K
- Earning Date
- NXTC 05-05-2025
- BLRX 05-27-2025
- Dividend Yield
- NXTC N/A
- BLRX N/A
- EPS Growth
- NXTC N/A
- BLRX N/A
- EPS
- NXTC N/A
- BLRX N/A
- Revenue
- NXTC N/A
- BLRX $28,940,000.00
- Revenue This Year
- NXTC N/A
- BLRX N/A
- Revenue Next Year
- NXTC N/A
- BLRX N/A
- P/E Ratio
- NXTC N/A
- BLRX N/A
- Revenue Growth
- NXTC N/A
- BLRX 502.92
- 52 Week Low
- NXTC $0.22
- BLRX $2.30
- 52 Week High
- NXTC $1.82
- BLRX $35.60
- Technical
- Relative Strength Index (RSI)
- NXTC 44.58
- BLRX 48.07
- Support Level
- NXTC $0.22
- BLRX $2.30
- Resistance Level
- NXTC $0.44
- BLRX $3.09
- Average True Range (ATR)
- NXTC 0.06
- BLRX 0.22
- MACD
- NXTC 0.02
- BLRX 0.06
- Stochastic Oscillator
- NXTC 86.11
- BLRX 79.33
About NXTC NextCure Inc.
NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.
About BLRX BioLineRx Ltd.
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has an off-strategy, legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.